Base de dados : MEDLINE
Pesquisa : D02.145.074.722.229.199 [Categoria DeCS]
Referências encontradas : 23370 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2337 ir para página                         

  1 / 23370 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449208
[Au] Autor:Maggio N; Shavit Stein E; Segal M
[Ad] Endereço:Department of Neurology, The Chaim Sheba Medical Center, Tel HaShomer, Israel.
[Ti] Título:Complex modulation by stress of the effect of seizures on long term potentiation in mouse hippocampal slices.
[So] Source:Hippocampus;27(8):860-870, 2017 Aug.
[Is] ISSN:1098-1063
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Stress has a profound effect on ability to express neuronal plasticity, learning, and memory. Likewise, epileptic seizures lead to massive changes in brain connectivity, and in ability to undergo long term changes in reactivity to afferent stimulation. In this study, we analyzed possible long lasting interactions between a stressful experience and reactivity to pilocarpine, on the ability to produce long term potentiation (LTP) in a mouse hippocampus. Pilocarpine lowers paired pulse potentiation as well as LTP in CA1 region of the mouse hippocampal slice. When stress experience precedes exposure to pilocarpine, it protects the brain from the lasting effect of pilocarpine. When stress follows pilocarpine, it exacerbates the effect of the drug, to produce a long lasting reduction in LTP. These changes are accompanied by a parallel change in blood corticosterone level. A single exposure to selective mineralo- or gluco-corticosterone (MR and GR, respectively) agonists and antagonists can mimic the stress effects, indicating that GR's underlie the lasting detrimental effects of stress whereas MRs are instrumental in counteracting the effects of stress. These studies open a new avenue of understanding of the interactive effects of stress and epileptic seizures on brain plasticity.
[Mh] Termos MeSH primário: Hipocampo/fisiopatologia
Potenciação de Longa Duração/fisiologia
Estado Epiléptico/patologia
Estado Epiléptico/fisiopatologia
Estresse Psicológico/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Anticonvulsivantes/farmacologia
Atropina/farmacologia
Corticosterona/sangue
Diazepam/farmacologia
Modelos Animais de Doenças
Estimulação Elétrica
Hipocampo/efeitos dos fármacos
Técnicas In Vitro
Potenciação de Longa Duração/efeitos dos fármacos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Agonistas Muscarínicos/toxicidade
Antagonistas Muscarínicos/farmacologia
Pilocarpina/toxicidade
Estado Epiléptico/induzido quimicamente
Estado Epiléptico/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Muscarinic Agonists); 0 (Muscarinic Antagonists); 01MI4Q9DI3 (Pilocarpine); 7C0697DR9I (Atropine); Q3JTX2Q7TU (Diazepam); W980KJ009P (Corticosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1002/hipo.22736


  2 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470123
[Au] Autor:Dojo K; Yamaguchi Y; Fustin JM; Doi M; Kobayashi M; Okamura H
[Ad] Endereço:Department of Systems Biology, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
[Ti] Título:Carbachol Induces Phase-dependent Phase Shifts of Per1 Transcription Rhythms in Cultured Suprachiasmatic Nucleus Slices.
[So] Source:J Biol Rhythms;32(2):101-108, 2017 Apr.
[Is] ISSN:1552-4531
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Among nonphotic stimulants, a classic cholinergic agonist, carbachol, is known to have a strong and unique phase-resetting effect on the circadian clock: Intracerebroventricular carbachol treatment causes phase delays during the subjective early night and phase advances in the subjective late night, but the effects of this drug on the suprachiasmatic nucleus (SCN) in vivo and in vitro are still controversial. In the present study, we succeeded in reproducing the biphasic phase-shifting effect of carbachol on clock gene expression in organotypic SCN slices prepared from mice carrying a Per1-promoter fused luciferase gene ( Per1-luc). Since this biphasic effect of carbachol in Per1-luc SCN was prevented by atropine but not by mecamylamine, we concluded that these phase shifts were muscarinic receptor-dependent. Next, we analyzed the expression of muscarinic receptors in the SCN by in situ hybridization and found that M3 and M4 subtypes were expressed in SCN cells. These signals appeared neonatally and reached adult levels at postnatal day 10. Together, these findings suggest that carbachol has a phase-dependent phase-shifting effect on the SCN clock through muscarinic receptor subtypes expressed in the SCN.
[Mh] Termos MeSH primário: Carbacol/farmacologia
Agonistas Colinérgicos/farmacologia
Ritmo Circadiano/efeitos dos fármacos
Proteínas Circadianas Period/genética
Núcleo Supraquiasmático/efeitos dos fármacos
Núcleo Supraquiasmático/fisiologia
Transcrição Genética
[Mh] Termos MeSH secundário: Animais
Animais Recém-Nascidos
Atropina/farmacologia
Relógios Circadianos/efeitos dos fármacos
Expressão Gênica
Luciferases/genética
Mecamilamina/farmacologia
Camundongos
Atividade Motora
Antagonistas Muscarínicos/farmacologia
Antagonistas Nicotínicos/farmacologia
Técnicas de Cultura de Órgãos
Regiões Promotoras Genéticas
Receptores Muscarínicos/genética
Receptores Muscarínicos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinergic Agonists); 0 (Muscarinic Antagonists); 0 (Nicotinic Antagonists); 0 (Per1 protein, mouse); 0 (Period Circadian Proteins); 0 (Receptors, Muscarinic); 6EE945D3OK (Mecamylamine); 7C0697DR9I (Atropine); 8Y164V895Y (Carbachol); EC 1.13.12.- (Luciferases)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180126
[Lr] Data última revisão:
180126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1177/0748730417691205


  3 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743514
[Au] Autor:Herbert J; Thiermann H; Worek F; Wille T
[Ad] Endereço:Bundeswehr Institute of Pharmacology and Toxicology, Neuherbergstrasse 11, 80937 Munich, Germany.
[Ti] Título:Precision cut lung slices as test system for candidate therapeutics in organophosphate poisoning.
[So] Source:Toxicology;389:94-100, 2017 08 15.
[Is] ISSN:1879-3185
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Standard therapeutic options in organophosphate (OP) poisoning are limited to the administration of atropine and oximes, a regimen often lacking in efficacy and applicability. Treatment alternatives are needed, preferably covering a broad spectrum of OP intoxications. Although recent research yielded several promising compounds, e.g. bioscavengers, modulators of the muscarinic acetylcholine (ACh) receptor or bispyridinium non-oximes, these substances still need further evaluation, especially regarding effects on the potentially lethal respiratory symptoms of OP poisoning. Aim of this study was the development of an applicable and easy method to test the therapeutic efficiency of such substances. For this purpose, airway responsiveness in viable precision cut lung slices (PCLS) from rats was analysed. We showed that ACh-induced airway contractions were spontaneously reversible in non-poisoned PCLS, whereas in OP poisoned PCLS, contractions were irreversible. This effect could be antagonized by addition of the standard therapeutic atropine, thereby presenting a clear indication for treatment efficiency. Now, candidate therapeutic compounds can be evaluated, based on their ability to counteract the irreversible airway contraction in OP poisoned PCLS.
[Mh] Termos MeSH primário: Antídotos/farmacologia
Atropina/farmacologia
Broncoconstrição/efeitos dos fármacos
Broncodilatadores/farmacologia
Descoberta de Drogas/métodos
Pulmão/efeitos dos fármacos
Antagonistas Muscarínicos/farmacologia
Contração Muscular/efeitos dos fármacos
Músculo Liso/efeitos dos fármacos
Agentes Neurotóxicos/toxicidade
Intoxicação por Organofosfatos/tratamento farmacológico
Organofosfatos/toxicidade
[Mh] Termos MeSH secundário: Acetilcolina/farmacologia
Animais
Relação Dose-Resposta a Droga
Pulmão/fisiopatologia
Masculino
Músculo Liso/fisiopatologia
Intoxicação por Organofosfatos/fisiopatologia
Ratos Wistar
Fatores de Tempo
Técnicas de Cultura de Tecidos
Sobrevivência de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antidotes); 0 (Bronchodilator Agents); 0 (Muscarinic Antagonists); 0 (Nerve Agents); 0 (Organophosphates); 7C0697DR9I (Atropine); N9YNS0M02X (Acetylcholine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  4 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773388
[Au] Autor:Marín-Sáez J; Romero-González R; Garrido Frenich A
[Ad] Endereço:Department of Chemistry and Physics, Analytical Chemistry Area, University of Almería, Research Centre for Agricultural and Food Biotechnology (BITAL), Agrifood Campus of International Excellence ceiA3(,) Carretera de Sacramento s/n, E-04120, Almería, Spain.
[Ti] Título:Enantiomeric determination and evaluation of the racemization process of atropine in Solanaceae seeds and contaminated samples by high performance liquid chromatography-tandem mass spectrometry.
[So] Source:J Chromatogr A;1474:79-84, 2016 Nov 25.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A new method has been developed for the enantioselective separation of (-) and (+) hyoscyamine in Solanaceaes seeds and contaminated buckwheat. Chromatographic separation was optimized, evaluating two chiral columns, Chirobiotic V and Chiralpal-AY3. Better resolution was obtained using a Chiralpak-AY3 column, utilizing as mobile phase ethanol (0.1% diethanolamine). An extraction procedure based on a modified QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) was applied, using water and acetonitrile containing 1% of acetic acid, and a clean-up step utilizing primary secondary amine (PSA) and graphitized carbon black (GCB) as sorbents. The extract was diluted with ethanol (50/:50, v/v) prior to chromatographic analysis, and the separation was carried out avoiding the racemization during this stage. Enantiomerization process of atropine was studied in samples at different conditions such as temperature (30, 50 and 80°C) and pH (3, 5, 7 and 9), observing that racemization occurs at high pH (9) and temperature (80°C). Stramonium and Brugmansia seeds were analyzed and the concentration of (-)-hyoscyamine was 1500mg/kg and 320mg/kg respectively. Contaminated buckwheat was also determined and (-)-hyoscyamine was detected at 170µg/kg.
[Mh] Termos MeSH primário: Atropina/química
Solanaceae/química
[Mh] Termos MeSH secundário: Atropina/isolamento & purificação
Cromatografia Líquida de Alta Pressão
Datura stramonium/química
Fagopyrum/química
Concentração de Íons de Hidrogênio
Hiosciamina/análise
Indicadores e Reagentes
Limite de Detecção
Reprodutibilidade dos Testes
Sementes/química
Solventes
Estereoisomerismo
Espectrometria de Massas em Tandem
Temperatura Ambiente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indicators and Reagents); 0 (Solvents); 7C0697DR9I (Atropine); PX44XO846X (Hyoscyamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873551
[Au] Autor:Cirlini M; Demuth TM; Biancardi A; Rychlik M; Dall'Asta C; Bruni R
[Ad] Endereço:Department of Food and Drug - LS9 Interlab Group, University of Parma, Via G.P. Usberti 95/a, 43134 Parma, Italy.
[Ti] Título:Are tropane alkaloids present in organic foods? Detection of scopolamine and atropine in organic buckwheat (Fagopyron esculentum L.) products by UHPLC-MS/MS.
[So] Source:Food Chem;239:141-147, 2018 Jan 15.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A closer monitoring of tropane alkaloids (TA) in foods is now recommended by the European Commission, following a series of alerts related to the contamination of buckwheat with weeds of the genus Datura. A novel, accurate UHPLC-MS/MS method was developed and validated for the rapid detection of scopolamine and atropine in buckwheat foods. A suitable extraction protocol was set up to maximize recoveries and detection limits in different raw, processed and baked foods. The method offers good performances in terms of sensitivity, accuracy and precision, with LOQs at 0.04 and 0.10µg/kg. The established method is suitable for routine determination of trace levels of TA and was applied to 26 different buckwheat-derived organic foods, detecting TA in 3 samples (13.9-83.9µg/kg for atropine and 5.7-10.4µg/kg for scopolamine). Only in one case the level of contamination was relevant in terms of food safety.
[Mh] Termos MeSH primário: Alimentos Orgânicos
[Mh] Termos MeSH secundário: Alcaloides
Atropina
Cromatografia Líquida de Alta Pressão
Fagopyrum
Seres Humanos
Hidrobrometo de Escopolamina
Espectrometria de Massas em Tandem
Tropanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Tropanes); 451IFR0GXB (Scopolamine Hydrobromide); 7C0697DR9I (Atropine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE


  6 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28977590
[Au] Autor:Foradori CD; Whitlock BK; Daniel JA; Zimmerman AD; Jones MA; Read CC; Steele BP; Smith JT; Clarke IJ; Elsasser TH; Keisler DH; Sartin JL
[Ad] Endereço:Department of Anatomy, Physiology & Pharmacology, Auburn University, Auburn, Alabama 36849.
[Ti] Título:Kisspeptin Stimulates Growth Hormone Release by Utilizing Neuropeptide Y Pathways and Is Dependent on the Presence of Ghrelin in the Ewe.
[So] Source:Endocrinology;158(10):3526-3539, 2017 Oct 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although kisspeptin is the primary stimulator of gonadotropin-releasing hormone secretion and therefore the hypothalamic-pituitary-gonadal axis, recent findings suggest kisspeptin can also regulate additional neuroendocrine processes including release of growth hormone (GH). Here we show that central delivery of kisspeptin causes a robust rise in plasma GH in fasted but not fed sheep. Kisspeptin-induced GH secretion was similar in animals fasted for 24 hours and those fasted for 72 hours, suggesting that the factors involved in kisspeptin-induced GH secretion are responsive to loss of food availability and not the result of severe negative energy balance. Pretreatment with the neuropeptide Y (NPY) Y1 receptor antagonist, BIBO 3304, blocked the effects of kisspeptin-induced GH release, implicating NPY as an intermediary. Kisspeptin treatment induced c-Fos in NPY and GH-releasing hormone (GHRH) cells of the arcuate nucleus. The same kisspeptin treatment resulted in a reduction in c-Fos in somatostatin (SS) cells in the periventricular nucleus. Finally, blockade of systemic ghrelin release or antagonism of the ghrelin receptor eliminated or reduced the ability of kisspeptin to induce GH release, suggesting the presence of ghrelin is required for kisspeptin-induced GH release in fasted animals. Our findings support the hypothesis that during short-term fasting, systemic ghrelin concentrations and NPY expression in the arcuate nucleus rise. This permits kisspeptin activation of NPY cells. In turn, NPY stimulates GHRH cells and inhibits SS cells, resulting in GH release. We propose a mechanism by which kisspeptin conveys reproductive and hormone status onto the somatotropic axis, resulting in alterations in GH release.
[Mh] Termos MeSH primário: Grelina/metabolismo
Hormônio do Crescimento/efeitos dos fármacos
Kisspeptinas/farmacologia
Neuropeptídeo Y/metabolismo
Células Secretoras de Somatostatina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Núcleo Arqueado do Hipotálamo/efeitos dos fármacos
Núcleo Arqueado do Hipotálamo/metabolismo
Arginina/análogos & derivados
Arginina/farmacologia
Atropina/farmacologia
Jejum/metabolismo
Feminino
Imunofluorescência
Hormônio do Crescimento/secreção
Hormônio Liberador de Hormônio do Crescimento
Antagonistas Muscarínicos/farmacologia
Oligopeptídeos/farmacologia
Proteínas Proto-Oncogênicas c-fos/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-fos/metabolismo
Receptores de Grelina/antagonistas & inibidores
Receptores de Neuropeptídeo Y/antagonistas & inibidores
Ovinos
Carneiro Doméstico
Células Secretoras de Somatostatina/secreção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (GHRP-6, Lys(3)-); 0 (Ghrelin); 0 (Kisspeptins); 0 (Muscarinic Antagonists); 0 (Neuropeptide Y); 0 (Oligopeptides); 0 (Proto-Oncogene Proteins c-fos); 0 (Receptors, Ghrelin); 0 (Receptors, Neuropeptide Y); 7C0697DR9I (Atropine); 9002-72-6 (Growth Hormone); 9034-39-3 (Growth Hormone-Releasing Hormone); 94ZLA3W45F (Arginine); O35HK034KO (BIBO 3304)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00303


  7 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28700617
[Au] Autor:Garabedian C; Champion C; Servan-Schreiber E; Butruille L; Aubry E; Sharma D; Logier R; Deruelle P; Storme L; Houfflin-Debarge V; De Jonckheere J
[Ad] Endereço:Univ. Lille, EA 4489 - Perinatal Environment and Health, Lille, France.
[Ti] Título:A new analysis of heart rate variability in the assessment of fetal parasympathetic activity: An experimental study in a fetal sheep model.
[So] Source:PLoS One;12(7):e0180653, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Analysis of heart rate variability (HRV) is a recognized tool in the assessment of autonomic nervous system (ANS) activity. Indeed, both time and spectral analysis techniques enable us to obtain indexes that are related to the way the ANS regulates the heart rate. However, these techniques are limited in terms of the lack of thresholds of the numerical indexes, which is primarily due to high inter-subject variability. We proposed a new fetal HRV analysis method related to the parasympathetic activity of the ANS. The aim of this study was to evaluate the performance of our method compared to commonly used HRV analysis, with regard to i) the ability to detect changes in ANS activity and ii) inter-subject variability. This study was performed in seven sheep fetuses. In order to evaluate the sensitivity and specificity of our index in evaluating parasympathetic activity, we directly administered 2.5 mg intravenous atropine, to inhibit parasympathetic tone, and 5 mg propranolol to block sympathetic activity. Our index, as well as time analysis (root mean square of the successive differences; RMSSD) and spectral analysis (high frequency (HF) and low frequency (LF) spectral components obtained via fast Fourier transform), were measured before and after injection. Inter-subject variability was estimated by the coefficient of variance (%CV). In order to evaluate the ability of HRV parameters to detect fetal parasympathetic decrease, we also estimated the effect size for each HRV parameter before and after injections. As expected, our index, the HF spectral component, and the RMSSD were reduced after the atropine injection. Moreover, our index presented a higher effect size. The %CV was far lower for our index than for RMSSD, HF, and LF. Although LF decreased after propranolol administration, fetal stress index, RMSSD, and HF were not significantly different, confirming the fact that those indexes are specific to the parasympathetic nervous system. In conclusion, our method appeared to be effective in detecting parasympathetic inhibition. Moreover, inter-subject variability was much lower, and effect size higher, with our method compared to other HRV analysis methods.
[Mh] Termos MeSH primário: Feto/fisiologia
Frequência Cardíaca/fisiologia
Sistema Nervoso Parassimpático/fisiologia
[Mh] Termos MeSH secundário: Administração Intravenosa
Animais
Atropina/administração & dosagem
Atropina/farmacologia
Gasometria
Feminino
Feto/efeitos dos fármacos
Frequência Cardíaca/efeitos dos fármacos
Modelos Animais
Sistema Nervoso Parassimpático/efeitos dos fármacos
Propranolol/administração & dosagem
Propranolol/farmacologia
Ovinos
Estresse Fisiológico/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
7C0697DR9I (Atropine); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180653


  8 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28682887
[Au] Autor:Wang YR; Bian HL; Wang Q
[Ad] Endereço:aDepartment of Ophthalmology, The People's Hospital of Yan'an bDepartment of Ophthalmology, Affiliated Hospital of Yan'an University, Yan'an, China.
[Ti] Título:Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial.
[So] Source:Medicine (Baltimore);96(27):e7371, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study aimed to assess the efficacy and safety of atropine 0.5% eyedrops (ATE) for the treatment of children with low myopia (LM). METHODS: In this study, a total of 126 children with LM were randomly divided into an intervention group (administered 0.5% ATE) and a control group (administered a placebo), with 63 children in each group. The outcome measurements were changes in the spherical equivalent (SE), and axial length (AL), as well as adverse events (AEs). RESULTS: Compared with placebo, administration of 0.5% ATE led to less progression in LM, as measured by SE, and less increase in AL (P < .01). In addition, no serious AEs occurred in both the groups. CONCLUSION: About 0.5% ATE was efficacious and safe for controlling myopia in children with LM.
[Mh] Termos MeSH primário: Atropina/administração & dosagem
Antagonistas Muscarínicos/administração & dosagem
Miopia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oftálmica
Atropina/efeitos adversos
Comprimento Axial do Olho/efeitos dos fármacos
Criança
Feminino
Seres Humanos
Masculino
Antagonistas Muscarínicos/efeitos adversos
Soluções Oftálmicas
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Muscarinic Antagonists); 0 (Ophthalmic Solutions); 7C0697DR9I (Atropine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007371


  9 / 23370 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28671922
[Au] Autor:Gizzi C; Mohamed-Noriega J; Murdoch I
[Ad] Endereço:*Moorfields Eye Hospital, NHS Trust ‡NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK †DIBINEM, University of Bologna, Bologna, Italy §Department of Ophthalmology, University Hospital, UANL, Monterrey, México.
[Ti] Título:A Case of Bilateral Pigment Dispersion Syndrome Following Many Years of Uninterrupted Treatment With Atropine 1% for Bilateral Congenital Cataracts.
[So] Source:J Glaucoma;26(10):e225-e228, 2017 Oct.
[Is] ISSN:1536-481X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Describe an unusual case of bilateral pigment dispersion syndrome (PDS) following years of uninterrupted treatment with atropine 1% for bilateral congenital cataracts, speculate on potential mechanisms leading to this condition. DESIGN: This is a case report. CASE: A 45-year-old white patient on long-term treatment with atropine 1% ointment since his infancy for bilateral congenital cataracts developed PDS with secondary ocular hypertension. RESULTS: The patient showed all the hallmarks of PDS with secondary ocular hypertension. An anterior segment Swept-Source optical coherence tomography was obtained to review the iris profile. The patient showed good pressure response to topical prostaglandin therapy. CONCLUSIONS: This is the second case report of PDS in a patient with chronic use of topical atropine. The proposed mechanisms for pigment dispersion are discussed and the possibility raised of dispersion being a potential side effect of the drug.
[Mh] Termos MeSH primário: Atropina/efeitos adversos
Catarata/tratamento farmacológico
Glaucoma de Ângulo Aberto/induzido quimicamente
Pressão Intraocular/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Tópica
Atropina/administração & dosagem
Relação Dose-Resposta a Droga
Glaucoma de Ângulo Aberto/diagnóstico
Glaucoma de Ângulo Aberto/fisiopatologia
Seres Humanos
Masculino
Meia-Idade
Midriáticos/administração & dosagem
Midriáticos/efeitos adversos
Pomadas
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mydriatics); 0 (Ointments); 7C0697DR9I (Atropine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1097/IJG.0000000000000717


  10 / 23370 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28654639
[Au] Autor:Chen Z; Liu L; Tu J; Qin G; Su W; Geng X; Chen X; Wu H; Pan W
[Ad] Endereço:Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
[Ti] Título:Improvement of atropine on esophagogastric junction observation during sedative esophagogastroduodenoscopy.
[So] Source:PLoS One;12(6):e0179490, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND STUDY AIMS: Although sedation esophagogastroduodenoscopy (EGD) is now widely used, previous research has reported that sedation during EGD exhibits a negative effect on esophagogastric junction (EGJ) exposure. Atropine might improve EGJ exposure, as noted in clinical practice. The aim of this study was to examine whether sedation had a negative effect on EGJ observation in the Chinese population, and whether atropine had some ability to act as an antidote to this unexpected secondary effect of sedation. PATIENTS AND METHODS: In this cross-sectional study, subjects were divided into the following three groups according to the methods of EGD examination: the non-sedation group, the propofol-fentanyl combined sedation group and the combined sedation with atropine administration group. The EGJ observation was assessed by a key photograph taken with the endoscopic camera 1 cm from the EGJ, which was rated on the following four-degree scale: excellent (score = 4), good (score = 3), fair (score = 2) and poor (score = 1). RESULTS: The EGJ exposure was better in the sedation group administered atropine (score = 2.64±1.05) than in the sedation group (score = 1.99±1.08, P<0.05) but not as good as in the non-sedation group (score = 3.24±1.12, P<0.05). Reduced detection of EGJ diseases in the sedation group was also found, compared to the non-sedation group (P<0.05). Only the use of atropine (OR = 2.381, 95%CI: 1.297-4.371, P = 0.005) was independently associated with excellent observation of the EGJ during sedation EGD. CONCLUSIONS: Combined propofol-fentanyl sedation reduces the extent of exposure of the EGJ during EGD and reduces the detection of EGJ diseases. The application of atropine in the sedation endoscopy examination helped to achieve better EGJ observation, but still cannot achieve an equal extent of exposure compared to non-sedation EGD.
[Mh] Termos MeSH primário: Atropina
Dispepsia/diagnóstico
Endoscopia do Sistema Digestório/métodos
Junção Esofagogástrica/diagnóstico por imagem
Refluxo Gastroesofágico/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Estudos Transversais
Dispepsia/diagnóstico por imagem
Feminino
Fentanila/uso terapêutico
Refluxo Gastroesofágico/diagnóstico por imagem
Seres Humanos
Hipnóticos e Sedativos/uso terapêutico
Masculino
Meia-Idade
Propofol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 7C0697DR9I (Atropine); UF599785JZ (Fentanyl); YI7VU623SF (Propofol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179490



página 1 de 2337 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde